Navigation Links
The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018
Date:12/14/2009

WALTHAM, Mass., Dec. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launches of several new agents, the atrial fibrillation drug market will increase more than sevenfold from $790 million in 2008 to $6.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Atrial Fibrillation finds that a strong pipeline of oral fixed-dose anticoagulants, most notably Boehringer Ingelheim's Pradaxa and Bayer/Johnson & Johnson's Xarelto, will drive significant market expansion. The market will also be driven by sales of the antiarrhythmic agent dronedarone (Sanofi-Aventis's Multaq), which will take share from class IC and class III antiarrhythmics to capture 11 percent of the total atrial fibrillation patient share in 2018. The report forecasts that Multaq will garner sales of $660 million in 2018.

"Multaq is the first antiarrhythmic to demonstrate a reduction in the risk of hospitalization due to cardiovascular causes in patients with paroxysmal or persistent atrial fibrillation," said Decision Resources Analyst Ben Kong, MBBS. "Physician enthusiasm for Multaq reflects the growing importance of clinically relevant outcomes in clinical trials involving antiarrhythmic therapies."

The report also finds that Cardiome/Astellas's Kynapid will provide an attractive alternative to electrical cardioversion, particularly in the U.S. intravenous cardioversion market, which is currently dominated by branded agents. In the U.S. alone, Kynapid will achieve sales of $130 million in 2018.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com .

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    For more information, contact:

    Decision Resources                    Decision Resources, Inc.
    Christopher Comfort                   Elizabeth Marshall
    781-296-2597                          781-296-2563
    ccomfort@dresources.com               emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New General Manager, Transition to New Raleigh Offices Highlight Datatrials Expansion of North American Operations
2. deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
3. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
4. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
5. Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat
6. Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25% Annually Over the Next Five Years
7. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
8. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
9. Reportlinker Adds Biotechnology Instrumentation - International Market Trends
10. Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective
11. Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... ... Big Island of Hawaii, is pleased to announce the first Delos Wellness Signature™ ... MacArthur Sotheby’s International Realty is working together with listing agent Kelly Allen, R(S) ...
(Date:8/21/2017)... , ... August 21, 2017 , ... ... is utilizing its extensive experience with Health Economics and Outcomes Research (HEOR) and ... Record data. In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 ...
(Date:8/18/2017)... ... August 18, 2017 , ... Producers of the ... Hybrids, Inc. in an upcoming episode, scheduled to broadcast fourth quarter 2017. American ... Federal Hybrids, the independent, family-owned seed company. Educating audiences about its broad portfolio ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... cancer research and personalized medicine, today announced the launch of a new breast ... Missouri. The study’s goal is to evaluate the potential for early detection of ...
Breaking Biology Technology:
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):